Marinus Charts The Way Forward For Ganaxolone Amid Business Challenges
Executive Summary
Phase II results for Marinus’s ganaxolone in postpartum depression are a mixed bag, but the US biotech sees potential in this and other neurological indications, probably with partners.
You may also be interested in...
Reviving A Longsuffering Neuro Company: The Marinus Story
Marinus Pharmaceuticals’ CEO spoke candidly to In Vivo about breathing new life into ultra-rare epilepsy disorder drug ganaxolone.
Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
Marinus Finds Silver Lining In Ganaxolone Trial Miss
The biotech announces another poor performance for its lead drug candidate, but puts a positive spin on the data and plans continued development.